Subconjunctival Bevacizumab and Recurrent Pterygium
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
A study to research whether subconjunctival bevacizumab injection may potentially suppress
neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium.